Fda

The FDA unveiled the Chemical Contaminants Transparency Tool, a searchable online database that provides a list of chemical contaminant types and levels used to evaluate possible harm in foods meant for human consumption.

The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press release from Johnson & Johnson.

  The FDA approved an expanded label for Iluvien, which is now indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye, according to a press release from ANI Pharmaceuticals.

The FDA released results from its investigation of benzene in acne products containing benzoyl peroxide. In light of these findings, the American Academy of Dermatology updated its statement on benzoyl peroxide in personal care products.

The United States Senate Committee on Health, Education, Labor and Pensions voted to advance the nominations of probable new NIH and FDA leaders to the full senate.

  The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and older with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive.

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription Drug User Fee Act date of Oct. 23, according to a press release from Sydnexis.

The FDA approved Celltrion’s omalizumab biosimilar, Omlyclo, for the treatment of multiple conditions including asthma and food allergy, according to an agency press release.

Lawmakers grilled Martin Makary, MD, MPH, on transparency, his plans for mifepristone and his stance on the recently cancelled Vaccine Advisory Committee meeting during Thursday’s senate hearing to be the next FDA commissioner.